Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-Label Pilot Study to Evaluate the Efficacy and Safety of a Combination Treatment of Sonidegib (LDE225) and Buparlisib (BKM120) For the Treatment of Advanced Basal Cell Carcinomas

Next Previous
Trial Profile

An Open-Label Pilot Study to Evaluate the Efficacy and Safety of a Combination Treatment of Sonidegib (LDE225) and Buparlisib (BKM120) For the Treatment of Advanced Basal Cell Carcinomas

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 06 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Buparlisib (Primary) ; Sonidegib (Primary)
  • Indications Basal cell cancer; Basal cell nevus syndrome; Carcinoma; Skin cancer
  • Focus Therapeutic Use

Most Recent Events

  • 24 Apr 2017 Planned End Date changed from 31 Dec 2017 to 1 Jun 2017.
  • 13 Jun 2016 Status changed from recruiting to active, no longer recruiting.
  • 17 Feb 2015 Planned primary completion date changed from 1 Nov 2016 to 1 Feb 2017, as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top